Opus Genetics, Inc.
IRDHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Opus Genetics, Inc. (IRD) is listed under Biotechnology. The $361.1M market capitalization puts IRD squarely in small-cap range for its industry. It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease.
Market Cap
$361.1M
Beta
0.58
P/E (TTM)
—
P/E (Fwd)
-5.88
EPS (TTM)
$-1.29
EPS (Fwd)
$-0.74
ROE
-4796.5%
ROA
-48.1%
Cash
$88.8M
Total Debt
$36.2M
Free CF
-$38.6M
52W Change
243.4%
Annual Financials
Cash vs Debt
Where IRD stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, IRD finished 6.46% above its 150-day moving average ($4.18) and 21.25% above its 200-day moving average ($3.67). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is IRD overbought or oversold?
At the September 3, 2026 close, IRD's RSI(14) was 66.5, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $88.8M in cash and $36.2M in debt, IRD maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$38.6M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -4796.5%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $39.9M (2022) to $14.2M (2025), a 64% decline worth watching.
The relatively low beta of 0.58 suggests IRD is a less volatile holding compared to the broader index. With cash comfortably exceeding debt, IRD has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing IRD.